Sort   by:  
 Page size 
UnknownDifferential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.
Not available
S-EPMC5477216 | biostudies-literature
UnknownA metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.
Not available
S-EPMC7317707 | biostudies-literature
UnknownEndothelin-1 is increased in the plasma of patients hospitalised with Covid-19.
Not available
S-EPMC8941861 | biostudies-literature
UnknownEndothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19.
Not available
S-EPMC8084922 | biostudies-literature
UnknownNovel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium.
Not available
S-EPMC7716805 | biostudies-literature
UnknownSafety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study.
Not available
S-EPMC7070793 | biostudies-literature
UnknownLiver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF.
Not available
S-EPMC9805158 | biostudies-literature
UnknownEvaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease.
Not available
S-EPMC8016788 | biostudies-literature
UnknownDapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
Not available
S-EPMC7664959 | biostudies-literature
UnknownEffect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
Not available
S-EPMC7157181 | biostudies-literature
Sort   by:  
 Page size